Leo As Patent-Cliff Exposure & CMS Drug Spending Portfolio
Leo As (US): 7 reconciled FDA prescription therapies (5.0% 2025 to 2030 cliff risk), $116.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 7 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 5.0% |
| Primary Portfolio LOE Date | 2029-01-01 |
| 2024 CMS Total Public Spend | $116.4M |
| 2024 Medicare Part D Spend | $63.7M |
| 2024 Medicaid Spend | $52.7M |
| California HCAI SB 17 Filings | 4 WAC filings (max 21.5% 2-yr change) |